EUVIMEDObjevte EUVIMED
Crossref

Venetoclax Synergizes With Regorafenib for Colorectal Cancer by Targeting BCL‐2

Lijun Zhu, Weicheng Wang, Yuwen Dong, Xiao Han, Wei Zhang, Zhonghua Zhang, Wenjie Guo, Yanhong Gu iD

Molecular Carcinogenesis · 2025

DOI: 10.1002/mc.70017 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2025. Written by Lijun Zhu and 7 co-authors. Institution: Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, The First Clinical Medical College of Nanjing Medical Universi…. Major MEDLINE topics: Colorectal Neoplasms, Phenylurea Compounds, Pyridines, Sulfonamides. Cited 5 times so far (Crossref); 35 references. Funded by: This study was supported by National Natural Science Foundation of China (82273197) and Key project of Science and technology in Jiangsu Province (BG2024007)..

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Despite notable advancements in therapeutic modalities, many patients with colorectal cancer (CRC) exhibit inadequate response to regorafenib, largely due to the propensity for drug resistance. Deeper insights into the mechanism of CRC sensitivity to regorafenib therapy are urgently required. The antiapoptotic protein B‐cell lymphoma 2 (BCL‐2) is closely associated with a variety of malignancies. Therefore, this study investigated the role of BCL‐2 in promoting regorafenib resistance in colorectal cancer. Venetoclax, a BCL‐2 antagonist, potentiates the antitumor activity of regorafenib. The combination of regorafenib and Venetoclax inhibited the proliferation and promoted apoptosis of CRC cells and human umbilical vein endothelial cells in vitro by inhibiting tumor angiogenesis, promoting normalization of tumor blood vessels, and promoting immune cell infiltration and the release of immune cytotoxic factors. Although Venetoclax is primarily used clinically to treat hematological tumors, it has not yet been used to treat CRC. These findings provide new insights for the clinical treatment of CRC.

Subjects

MeSH terms (MEDLINE)

Colorectal NeoplasmsPhenylurea CompoundsPyridinesSulfonamidesProto-Oncogene Proteins c-bcl-2Bridged Bicyclo Compounds, HeterocyclicAntineoplastic Combined Chemotherapy ProtocolsHumansApoptosisCell ProliferationAnimalsDrug SynergismMiceXenograft Model Antitumor AssaysDrug Resistance, NeoplasmCell Line, TumorHuman Umbilical Vein Endothelial CellsNeovascularization, Pathologic

Author keywords

BCL‐2colorectal cancerregorafenibresistancevenetoclax

Substances

regorafenibPhenylurea CompoundsPyridinesSulfonamidesProto-Oncogene Proteins c-bcl-2venetoclaxBridged Bicyclo Compounds, HeterocyclicBCL2 protein, human

Authors and institutions

  • Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, The First Clinical Medical College of Nanjing Medical University, Nanjing Medical University, Nanjing, China.
  • Department of Oncology, Northern Jiangsu People's Hospital, Yangzhou, China.
  • Department of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
  • State Key Laboratory of Pharmaceutical Biotechnology, Department of Gastroenterology, Nanjing Drum Tower Hospital, School of Life Science, Nanjing University, Nanjing, People's Republic of China.

ORCID profiles: Yanhong Gu

Funding

  • This study was supported by National Natural Science Foundation of China (82273197) and Key project of Science and technology in Jiangsu Province (BG2024007).

Cite

APA

Zhu, L., Wang, W., Dong, Y., Han, X., Zhang, W., Zhang, Z., Guo, W., & Gu, Y. (2025). Venetoclax Synergizes With Regorafenib for Colorectal Cancer by Targeting BCL‐2. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70017

Vancouver

Zhu L, Wang W, Dong Y, Han X, Zhang W, Zhang Z, et al. Venetoclax Synergizes With Regorafenib for Colorectal Cancer by Targeting BCL‐2. Molecular Carcinogenesis. 2025. doi:10.1002/mc.70017

BibTeX
@article{Zhu2025,
  author = {Zhu, Lijun and Wang, Weicheng and Dong, Yuwen and Han, Xiao and Zhang, Wei and Zhang, Zhonghua and Guo, Wenjie and Gu, Yanhong},
  title = {Venetoclax Synergizes With Regorafenib for Colorectal Cancer by Targeting BCL‐2},
  journal = {Molecular Carcinogenesis},
  year = {2025},
  doi = {10.1002/mc.70017}
}
Start for free →